» Articles » PMID: 39859045

Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy

Overview
Publisher MDPI
Date 2025 Jan 25
PMID 39859045
Authors
Affiliations
Soon will be listed here.
Abstract

This case report highlights the use of continuous infusion of meropenem in a 42-year-old septic female patient with periprosthetic infection and end-stage renal disease receiving prolonged intermittent renal replacement therapy (PIRRT). Antibiotic infusion in patients receiving renal replacement therapy has its own peculiarities. There are many studies on the optimal dosing regimen for meropenem in renal dysfunction, but studies on the optimal infusion duration in these patients are limited. The patient was admitted with complaints of wounds, necrosis zones of the right upper limb, restriction of joint movements, and temperature increase up to 38 °C. The patient was treated with a continuous infusion of meropenem 2 g per day receiving renal replacement therapy three times a week (12 h). Also during hospitalization, the patient underwent hip disarticulation and excision of necrotic tissues. The patient was further transferred to a specialized nephrology department for further treatment. We believe that in this clinical case, the use of continuous infusion of meropenem in the complex therapy of sepsis in a patient with CKD undergoing PIRRT sessions helped to lead to clinical improvement in the patient. Further studies are needed.

References
1.
Cheikh Hassan H, Tang M, Djurdjev O, Langsford D, Sood M, Levin A . Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. Kidney Int. 2016; 90(4):897-904. DOI: 10.1016/j.kint.2016.07.013. View

2.
Yousif T, Pooyeh S, Hannemann J, Baumann J, Tauber R, Baumann K . Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes. Int J Clin Pharmacol Ther. 1999; 37(10):475-86. View

3.
Keller F . [Pharmacotherapy and kidney dysfunction]. Med Klin Intensivmed Notfmed. 2018; 114(5):444-451. DOI: 10.1007/s00063-018-0455-5. View

4.
Jamal J, Mat-Nor M, Mohamad-Nor F, Udy A, Wallis S, Lipman J . Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2014; 45(1):41-5. DOI: 10.1016/j.ijantimicag.2014.09.009. View

5.
OJeanson A, Larcher R, Le Souder C, Djebli N, Khier S . Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation. Eur J Drug Metab Pharmacokinet. 2021; 46(5):695-705. DOI: 10.1007/s13318-021-00709-w. View